Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
6.12 USD
7.75%
Updated:
May 15, 2024
Editas Medicine Inc
Total Liabilities & Equity
|
Editas Medicine Inc
Total Liabilities & Equity Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Liabilities & Equity
$440.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$134.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$56.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$93B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$22.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$34.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
27%
|
See Also
What is Editas Medicine Inc's Total Liabilities & Equity?
Total Liabilities & Equity
440.3m
USD
440.3m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Liabilities & Equity amounts to 440.3m USD.
What is Editas Medicine Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
3%
3%
Over the last year, the Total Liabilities & Equity growth was -5%. The average annual Total Liabilities & Equity growth rates for Editas Medicine Inc have been -17% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
